Related Experiment Video
Updated: Jul 3, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Body mass and glucocorticoid response in asthma
E Rand Sutherland1, Elena Goleva, Matthew Strand
1Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, J-220 Denver, CO 80206, USA. sutherlande@njc.org
Obesity in asthma patients is linked to a reduced response to dexamethasone, a key steroid treatment. Higher body mass index correlates with decreased effectiveness of this crucial asthma medication.
Area of Science:
- Pulmonary Medicine
- Endocrinology
- Immunology
Background:
- Obesity is a growing concern in asthma management.
- Glucocorticoids are a cornerstone therapy for asthma.
- The impact of obesity on glucocorticoid efficacy in asthma requires further investigation.
Purpose of the Study:
- To investigate the relationship between body mass index (BMI) and the response to glucocorticoids.
- To assess how BMI influences dexamethasone-induced effects in patients with and without asthma.
Main Methods:
- Adult subjects with and without asthma were assessed for lung function and BMI.
- Spirometric response to prednisone was measured.
- Dexamethasone-induced MKP-1 and TNF-alpha expression were analyzed in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage cells using PCR.
Main Results:
- Overweight/obese asthma patients showed reduced dexamethasone-induced MKP-1 expression in PBMCs and bronchoalveolar lavage cells compared to lean patients.
- Increased BMI correlated with decreased dexamethasone-induced MKP-1 and increased TNF-alpha expression in PBMCs of asthma patients.
- The ratio of TNF-alpha to MKP-1 increased with BMI in asthma patients, indicating a pro-inflammatory shift.
Conclusions:
- Elevated BMI is associated with a blunted in vitro response to dexamethasone in asthma patients.
- These findings suggest that obesity may impair glucocorticoid effectiveness in asthma.
- Further research is needed to explore therapeutic strategies for obese asthma patients.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
Asthma III: Clinical Manifestations
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Cushing Syndrome II: Pathophysiology